PT-141 vs Addyi for Low Libido in Women: Which Works Better?

Is PT-141 or Addyi better for low libido in women?

Quick answer

Neither PT-141 nor Addyi has proved superior in a direct head-to-head trial. PT-141 is used around planned sexual activity, while Addyi is taken nightly. The better fit depends on whether you prefer occasional treatment or a daily routine, plus which side effects and medical considerations you can manage.

Reviewed by Taylor Anderson, RN · Aesthetic Registered Nurse · Updated September 3, 2026

Key takeaways

PT-141 is an as-needed injection used around planned sexual activity; Addyi is a nightly tablet.
Positive analyses report roughly 0.5 to 0.7 additional satisfying sexual events per month, while a critical review found smaller or no added gains.
Nausea affected about 40% of participants in pivotal bremelanotide trials, compared with 1.3% taking placebo.
The available evidence does not establish a universal winner, so schedule, tolerability, health history, and expectations matter.
Get Hot or Die now prescribes and dispenses medication, but medication, price, coverage, and fulfillment details were not available for this comparison.

PT-141, also called bremelanotide, is used around planned sexual activity. Addyi, or flibanserin, is taken every night. Neither produces dramatic average gains for most women, and no direct head-to-head trial shows that one consistently beats the other.

Get Hot or Die now prescribes and dispenses medication. Its current medication, price, coverage, and fulfillment details were not available for this comparison. If you want help sorting your preferences before a medical conversation, take the Get Hot or Die personalized quiz.

Low libido can affect desire, energy, confidence, and intimacy. PT-141 and Addyi were studied for hypoactive sexual desire disorder (HSDD), a persistent reduction in desire that causes distress. The practical choice comes down to schedule, side effects, medical fit, and whether the average study benefit feels worthwhile to you.

How PT-141 and Addyi fit into your life

The main difference is easy to understand: one treatment is tied to a planned sexual experience, while the other asks you to follow a nightly routine.

Option	When it may fit	What to discuss with a clinician
Get Hot or Die	You want a current care and provider option before choosing a medication routine.	The current HOD medication, price, coverage, and fulfillment details were not available for this comparison.
PT-141 (bremelanotide)	You prefer treatment linked to planned sexual activity rather than a daily tablet.	The on-demand schedule, nausea risk, blood-pressure considerations, and your health history.
Addyi (flibanserin)	You prefer a consistent bedtime routine and do not need treatment tied to one specific event.	Daily adherence, current medicines, alcohol use, and whether the treatment fits your health history.

The medical literature describes bremelanotide as an on-demand subcutaneous injection and flibanserin as a bedtime tablet. A systematic review and meta-analysis of flibanserin and a review of clinical trials describe the two schedules and their different mechanisms.

What each treatment does

Bremelanotide acts through melanocortin pathways, including MC3 and MC4 receptors. Flibanserin affects serotonin signaling, including 5-HT1A and 5-HT2A receptors. The exact reason either treatment improves desire is not fully established.

Treatment	Schedule	Practical fit
PT-141/bremelanotide	Used before planned sexual activity.	Fits episodic use and does not require a nightly tablet.
Addyi/flibanserin	Taken at bedtime every day.	Fits continuous treatment and requires consistent adherence.

If desire tends to show up in specific moments, an as-needed treatment may feel more natural. If you want treatment to sit inside an established evening routine, a nightly tablet may be easier to remember. Neither schedule guarantees a better result.

What the studies say about results

Both drugs improved some desire and distress measures compared with placebo in clinical trials. The average benefit was modest, and the studies used different designs and outcome measures, so the numbers should not be treated as a direct contest.

Measure	PT-141/bremelanotide	Addyi/flibanserin	How to read it
Desire and distress	Phase 3 studies reported improvement in desire and reduction in related distress.	Trials and pooled analyses reported improvements in desire and related outcomes.	Both show a treatment signal, but average benefit varies across studies.
Satisfying sexual events	One 2025 abstract reported about 0.7 additional events per month.	A pooled review reported about 0.49 additional events per month.	These are small average differences and are not directly interchangeable.
Critical interpretation	One critical review reported no additional enjoyable events.	The same critical review described roughly one additional enjoyable experience every two months.	The meaning of the average result remains contested.
Head-to-head evidence	No direct comparison establishes superiority.	No direct comparison establishes superiority.	There is no universal winner.

A critical review of bremelanotide and flibanserin questioned whether the average trial gains translate into meaningful everyday improvement. A 2025 comparative analysis reported roughly 0.7 additional satisfying sexual events per month with bremelanotide and 0.5 to 1 with flibanserin, alongside changes in Female Sexual Function Index scores.

Those averages cannot tell you whether either treatment will restore your desire. They can help set expectations: the likely outcome is a measurable but limited average change, not an instant return to how you felt at 25.

Side effects may decide the choice

Bremelanotide's main burden tends to arrive around the time of use. Flibanserin's practical burden is taking a tablet every night and checking for interactions and safety concerns.

In pivotal bremelanotide trials, nausea occurred in about 40% of participants compared with 1.3% taking placebo. Flushing occurred in about 20.3% versus 0.3%, and headache in about 11.3% versus 1.9%. One review reported that nausea began after a median of about 30 minutes and lasted about 2.4 hours. The bremelanotide clinical review summarizes these findings.

Consideration	PT-141/bremelanotide	Addyi/flibanserin
Most prominent concern in the cited studies	Nausea, flushing, headache, and vomiting.	Nightly adherence and medicine or alcohol interactions.
Timing	Side effects may occur acutely after use.	The treatment experience depends on consistent daily use and individual response.
Medical review	Discuss nausea, blood-pressure and heart-rate findings, and personal health history.	Review medicines, alcohol use, health history, and the suitability of daily treatment.

A daily tablet is not automatically easier to tolerate, and an as-needed injection is not automatically more convenient. The side-effect pattern you can live with matters as much as the calendar reminder.

Check whether the evidence fits you

The cited studies largely focused on premenopausal women with HSDD. Low desire can also relate to medication effects, stress, relationship strain, pain, sleep, mood, hormonal changes, or another health issue. A clinician can help separate those possibilities before you commit to treatment.

Ask yourself:

Does low desire cause ongoing distress, or has it changed for another reason?
Would you rather plan treatment around sex or take something every night?
How would nausea or flushing affect your plans?
Which medicines, alcohol use, blood-pressure concerns, or other health factors need review?
What improvement would feel meaningful enough to continue treatment?

The FDA approved flibanserin in 2015 and bremelanotide in 2019 for HSDD in women, according to the published reviews. Approval does not determine which treatment fits one particular woman.

If PT-141 is the option you are considering, our guide to where to get PT-141 for women covers the practical questions to ask about care. If the broader issue is changing desire during perimenopause or menopause, see the hormones hub for related treatment topics.

What to remember

PT-141 is an as-needed treatment linked to planned sexual activity; Addyi is a nightly tablet.
Positive analyses report roughly 0.5 to 0.7 additional satisfying sexual events per month, while a critical review reported smaller or no added gains.
Nausea affected about 40% of participants in pivotal PT-141 trials and may appear soon after use.
No direct head-to-head trial establishes a universal winner.
Your routine, side-effect preferences, medicines, health history, and definition of meaningful improvement should shape the discussion.

Frequently asked questions

Is PT-141 the same as Vyleesi?

PT-141 is the name used for bremelanotide in the literature. Vyleesi is the brand name for bremelanotide, the as-needed injection discussed here.

Is Addyi taken only when sex is planned?

No. Addyi, or flibanserin, is taken as a daily bedtime tablet rather than around a specific sexual event.

Which one works faster?

PT-141 is timed around planned sexual activity, while Addyi is taken daily. That schedule difference is clearer than any claim that one works universally faster.

Does PT-141 work better than Addyi?

There is no reliable universal winner. Studies report modest, varying average effects, and no direct head-to-head trial establishes superiority.

What are the main side-effect tradeoffs?

Bremelanotide studies most often report nausea, flushing, headache, and vomiting. Addyi requires nightly adherence and a review of medicines, alcohol use, and health history.

How do I start?

Start by discussing your symptoms, health history, medicines, and preferred treatment routine with a qualified clinician. Get Hot or Die now prescribes and dispenses medication, but its current medication, price, coverage, and fulfillment details were not available for this comparison.

Sources

Ready to make a move?

Answer three questions to see the options, prices, and providers that fit your goals.

See My Plan

Questions women actually ask